

Resource Summary Report

Generated by ASWG on Aug 9, 2026

CD8 Antibody, anti-human, APC, REAfinity™

RRID:AB_2659237

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-110-679, RRID:AB_2659237

Antibody Information

URL: http://antibodyregistry.org/AB_2659237

Proper Citation: Miltenyi Biotec Cat# 130-110-679, RRID:AB_2659237

Target Antigen: CD8

Host Organism: human

Clonality: monoclonal

Comments: Applications: MACS Flow Cytometry

Antigen Distribution: T cells, NK cells

Antibody Name: CD8 Antibody, anti-human, APC, REAfinity™

Description: This monoclonal targets CD8

Target Organism: human

Clone ID: clone REA734

Antibody ID: AB_2659237

Vendor: Miltenyi Biotec

Catalog Number: 130-110-679

Record Creation Time: 20250820T042746+0000

Record Last Update: 20250820T190221+0000

Ratings and Alerts

No rating or validation information has been found for CD8 Antibody, anti-human, APC, REAfinity™.

No alerts have been found for CD8 Antibody, anti-human, APC, REAfinity™.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Vandoren R, et al. (2026) AIRRWAS integrates TCR-microbiome data to reveal how the gut microbiome shapes the circulating and mucosal T cell repertoire. Cell reports, 45(6), 117479.

Nunez D, et al. (2026) Case study of resecabtagene autoleucel in a subject with diffuse cutaneous systemic sclerosis treated in the RESET-SSc trial. Molecular therapy. Advances, 34(1), 201663.

Schmidlin T, et al. (2025) MR1-ligand cross-linking identifies vitamin B6 metabolites as TCR-reactive antigens. Cell reports methods, 5(8), 101120.

Augello M, et al. (2024) Association between SARS-CoV-2 RNAemia, skewed T cell responses, inflammation, and severity in hospitalized COVID-19 people living with HIV. iScience, 27(1), 108673.

Dolton G, et al. (2023) Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy. Cell, 186(16), 3333.

Wu L, et al. (2023) CD28-CAR-T cell activation through FYN kinase signaling rather than LCK enhances therapeutic performance. Cell reports. Medicine, 4(2), 100917.

Dolton G, et al. (2022) Emergence of immune escape at dominant SARS-CoV-2 killer T cell epitope. Cell, 185(16), 2936.